摘要
目的 探讨聚乙二醇干扰素α-2a注射液(商品名:派罗欣)联合利巴韦林在慢性丙型肝炎(丙肝)患者治疗中的价值。方法 76例慢性丙肝患者,采用随机数字表法分为对照组和观察组,每组38例。对照组患者采用干扰素联合利巴韦林治疗,观察组患者采用派罗欣联合利巴韦林治疗。对比两组患者临床疗效,治疗前后丙氨酸氨基转移酶(ALT)、谷草转氨酶(AST)水平,药物不良反应发生情况。结果 观察组的治疗总有效率为97.37%,高于对照组的84.21%,差异具有统计学意义(P<0.05)。治疗前,两组ALT、AST水平对比差异均无统计学意义(P>0.05);治疗后,观察组患者的ALT(39.29±8.16)U/L、AST(35.25±2.37)U/L均低于对照组的(45.79±9.16)、(42.59±3.16)U/L,差异具有统计学意义(P<0.05)。观察组患者的药物不良反应发生率为10.53%,与对照组的15.79%对比,差异无统计学意义(P>0.05)。结论 慢性丙肝患者采用派罗欣联合利巴韦林治疗能够获得满意的临床疗效,并可有效改善患者的肝功能,同时该药物方案的安全性良好。
Objective To discuss the value of combined use of peginterferon alfa-2a Solution for injection(trade name:Pegasys)and ribavirin in the treatment of chronic hepatitis C.Methods A total of 76 patients with chronic hepatitis C were randomly divided into control group and observation group by random numerical table,with 38 cases in each group.Patients in the control group were treated with interferon combined with ribavirin,and the patients in the observation group were treated with Pegasys combined with ribavirin.The clinical efficacy,alanine aminotransferase(ALT),aspartate aminotransferase(AST)levels before and after treatment,and the occurrence of adverse drug reactions were compared between the two groups.Results The total effective rate of the observation group was 97.37%,which was higher than 84.21%of the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in ALT and AST levels between the two groups(P>0.05).After treatment,the ALT(39.29±8.16)U/L and AST(35.25±2.37)U/L of the observation group were lower than(45.79±9.16)and(42.59±3.16)U/L of the control group,and the differences were statistically significant(P<0.05).The incidence of adverse drug reactions in the observation group was 10.53%,which was not statistically significant compared with 15.79%in the control group(P>0.05).Conclusion For patients with chronic hepatitis C,the combination of Pegasys and ribavirin can achieve satisfactory clinical efficacy and effectively improve the liver function of patients,and the drug regimen has a good safety.
作者
肖琴美
XIAO Qin-mei(Yuanmou County People's Hospital,Yuanmou 651300,China)
出处
《中国实用医药》
2022年第17期115-117,共3页
China Practical Medicine
